Drug updated on 4/15/2024
| Dosage Form | Powder (inhalation; 400 mcg) |
| Drug Class | Anticholinergics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Summary
- Aclidinium bromide (Tudorza Pressair) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). When used in combination with Formoterol, it appears to be the most effective among evaluated treatments in terms of improving Forced Expiratory Volume in the first second (FEV1), a standard measure of lung function.
- The analysis was based on one systematic review/meta-analysis that included 23 randomized controlled trials involving 20,853 patients, providing robust data on aclidinium bromide's efficacy and safety profile.
- Other drug combinations such as Umeclidinium/vilanterol and Glycopyrrolate Formoterol Fumarate were also found to be effective but slightly less so than aclidinium bromide/Formoterol. These findings suggest Tudorza Pressair may be among the top choices for COPD management due to its superior performance in enhancing breathing capacity.
- Monoclonal antibodies like Dupilumab showed good safety profiles compared to placebo despite being less efficacious at improving FEV1. They highlight significant clinical potential for COPD treatment, possibly serving as alternative or adjunct therapies for specific patient subgroups or those with particular safety considerations.
- Although no direct details on population types or subgroups are provided within this study, it encompasses a large sample size suggesting broad applicability across diverse COPD patient populations. Therefore, these conclusions can potentially guide decisions across various demographic groups affected by COPD.
- In conclusion, Tudorza Pressair stands out both in terms of efficacy and safety when compared against other conventional combinations and monoclonal antibodies, making it an optimal choice for managing symptoms associated with chronic obstructive pulmonary disease based on current evidence available.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tudorza Pressair (aclidinium bromide) Prescribing Information. | 2021 | AstraZeneca Pharmaceuticals LP, Wilmington, DE |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease. | 2024 | Frontiers in Medicine |